ClinicalTrials.gg
Active, not recruitingNCT06384976Updated Jan 13, 2025

KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

A Phase 2 interventional study of KYV-101 and Standard lymphodepletion regimen in Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive and Multiple Sclerosis, sponsored by Kyverna Therapeutics. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-01-13.

Sponsored by Kyverna Therapeutics · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 105 studies in Multiple Sclerosis, Chronic Progressive with a site in United States — 25 open to participants now, 38 under way, 9 of them phase 3. Multiple Sclerosis, Chronic Progressive · United States.

Planned enrollment
27th of 85
120 · median 59
Started
2024
with 10 others
Phase 2
18 of 105
3 open now
Primary completion
2027-04
later than 19 of 37 live
Registered
73rd of 105
by date

Among the 105 studies in Multiple Sclerosis, Chronic Progressive with a site in United States, this one is the 27th largest by planned enrollment of the 85 interventional ones that give a count, is one of 11 that started in 2024, is one of 18 in phase 2, reaches primary completion later than 19 of the 37 other live ones, and was the 73rd registered.

Multiple Sclerosis, Chronic Progressive

245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.

Browse Multiple Sclerosis, Chronic Progressive studies →

Open to participants now

25 of the 105 studies in Multiple Sclerosis, Chronic Progressive with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Multiple Sclerosis, Chronic Progressive with a site in United States, or all of them as a file.
02

Study summary

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis

Read the detailed description

Multiple sclerosis (MS) is an autoimmune and neurodegenerative disease in which lymphocytes at first attack the myelin sheaths within the central nervous system (CNS), accompanied or later followed by axonal damage. B cells play a central and multifunctional role in the immunopathogenesis of MS. B cells present antigen to T cells in stimulating a pro-inflammatory immune cascade, secrete pathogenic cytokines, moderate T cell and myeloid cell functions, form structural B cell meningeal follicles within the human central nervous system and produce pathogenic antibodies upon evolution to plasma cells.

CD19-targeted chimeric antigen receptor (CAR) T cells harness the ability of cytotoxic T cells to directly and specifically lyse target cells to effectively deplete B cells in the circulation and in lymphoid and potentially non-lymphoid tissues. KYV-101, a fully human anti-CD19 CAR T-cell therapy, will be investigated in adult subjects with refractory primary and secondary progressive multiple sclerosis.

03

Conditions studied

  • Multiple Sclerosis, Primary Progressive
  • Multiple Sclerosis, Secondary Progressive
  • Multiple Sclerosis
  • MS

Keywords

  • KYV-101
  • multiple sclerosis
  • autoimmune disease
  • anti-CD19 CAR-T therapy
  • cellular therapy
  • MS
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Subject must have a history of diagnosis of primary progressive or secondary progressive MS.
  2. History of treatment with anti-CD20 mAb with continuing evidence of worsening physical disability over a period of ≥6 months, with documented clinical disability progression within the 2 years prior to inclusion.

Key Exclusion Criteria:

  1. Monophasic disease, radiologically isolated syndrome, clinically isolated syndrome, progressive solitary sclerosis or relapsing-remitting disease as defined by the 2017 McDonald criteria.
  2. History of CNS or spinal cord tumor, metabolic or infectious cause of myelopathy, genetically inherited progressive CNS disorder, sarcoidosis, non-MS progressive neurologic condition or PML.
  3. Prior treatment with cellular therapy (CAR-T) or gene therapy product directed at any target
  4. History of or autologous stem cell transplant
  5. Evidence of active or infection
  6. Positive serology for
  7. Primary immunodeficiency
  8. History of splenectomy
  9. History of stroke, seizure, dementia, Parkinson's disease, coordination movement disorder, cerebellar diseases, psychosis, paresis, aphasia, and any other neurologic disorder investigator considers would increase the risk for the subject
  10. Impaired cardiac function or cardiac disease
  11. Previous or concurrent with the following exceptions:

    1. Adequately treated basal cell or squamous cell carcinoma (adequate wound healing is required prior to screening)
    2. In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 3 years prior to screening
    3. A primary malignancy which has been completely resected, or treated, and is in complete remission for at least 5 years prior to screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    KYV-101 CAR-T cells with lymphodepletion conditioning

    Dosing with KYV-101 CAR T cells

    Biological: KYV-101 · Drug: Standard lymphodepletion regimen

  • Active comparator
    Anti- CD20 mAb

    Dosing with anti-CD20 mAb

    Drug: Anti-CD20 mAB

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate efficacy of KYV-101

    Confirmed disability Progression on the EDSS scale. The EDSS scale ranges from 0 to 10 in 0.5- unit increments that represent higher levels of disability. Scoring is based on an examination by a neurologist.

    Time frame: at least 12 weeks

Secondary outcomes

  1. To characterize the safety and tolerability of KYV-101

    Incidence and severity of adverse events (AEs)

    Time frame: Up to 2 years

  2. To characterize the safety and tolerability of KYV-101

    Incidence and severity of adverse events of special interests (AESIs)

    Time frame: Up to 2 years

  3. To characterize the safety and tolerability of KYV-101

    Incidence and severity of serious adverse events (SAEs)

    Time frame: Up to 2 years

  4. To evaluate efficacy of KYV-101

    Composite Confirmed Disability Progression (CCPD)

    Time frame: up to 12 weeks

  5. To characterize the pharmacokinetics (PK)

    Levels of Chimeric antigen receptor positive (CAR-positive) T cell counts

    Time frame: Up to 2 years

  6. To characterize the pharmacokinetics (PK)

    Levels of CAR Transgene levels

    Time frame: Up to 2 years

  7. To characterize the Pharmacodynamics (PD)

    Levels of B cell in the blood

    Time frame: Up to 2 years

  8. To characterize the Pharmacodynamics (PD)

    Serum cytokines will be measured by multiplexed mesoscale discovery (MSD) assay and will include cytokines historically associated with potential CAR T toxicity (CRS and ICANS) such as gamma interferon (IFNg) and interleukin 6 (IL-6).

    Time frame: Up to 2 years

  9. To evaluate the immunogenicity (humoral response) of KYV-101

    Percentage of participants who develop anti-KYV-101 antibodies by immunoassays)

    Time frame: Up to 2 years

07

Study locations

1 site
08

References and documents

Publications

  • Silva BA, Miglietta E, Ferrari CC. Insights into the role of B cells in the cortical pathology of Multiple sclerosis: evidence from animal models and patients. Mult Scler Relat Disord. 2021 May;50:102845. doi: 10.1016/j.msard.2021.102845. Epub 2021 Feb 16. PubMed 33636613 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Apr 2027, 31 months after the start.

Of 25 phase 2 interventional studies under Multiple Sclerosis, Chronic Progressive, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 55. This study's planned 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2023
First posted
Apr 25, 2024
StartActual
Sep 20, 2024
Primary completionEst.
Apr 2027
CompletionEst.
Jan 2029
Last update
Jan 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06384976
Lead sponsor
Kyverna Therapeutics
Responsible party
Sponsor
First posted
Apr 25, 2024
Start date
Sep 20, 2024
Primary completion
Apr 2027 (estimated)
Completion
Jan 2029 (estimated)
Last update
Jan 13, 2025

Study contacts

MD
study director · Kyverna Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mivocabtagene autoleucel

Start the discussion